Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 0123 in Combination With Carboplatin and Etoposide in SCLC
NCT05815160Phase 1Terminated
- Sponsor
- Debiopharm
- Start
- May 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of zedoresertib in small cell lung cancer (SCLC) (2 arms), sponsored by Debiopharm. Primary endpoints: Dose-limiting Toxicities at 21 days, Treatment Emergent Adverse Events at 44 months and 2 more. Started May 2023; status: terminated.
02
Drugs
zedoresertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05815160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05815160.